Medical Advocates
HIV/HCV Coinfection
 
HIV Antiretroviral Drugs
HAART/ART: General Reports    Zidovudine
Abacavir                                     Peginterferons
 Atazanavir                                    
Darunavir                                     
Didanosine
Lopinavir
Maraviroc
Raltegravir
Ritonavir
Tenofovir
Tipranavir
 
HIV/HCV Main Page Main New/Newsworthy  Home Page
Last Update:  February 11, 2015  
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
HAART/ART General Reports
 

    Journal Papers, Abstracts, and Commentaries
 
 

Influence of hepatitis C virus coinfection on CD4+ T cells of HIV-infected patients receiving HAART.
 Shmagel KV, Saidakova EV, Korolevskaya LB,  et al 
AIDS. 2014 Aug 7.
 Abstract

HIV-Hepatitis C Virus Co-infection in the era of Direct-Acting Antivirals.
 Bichoupan K, Dieterich DT, Martel-Laferrière V. 
Curr HIV/AIDS Rep. 2014 Jul 5.
Abstract

Reversible hepatic decompensation following cessation of antiretroviral therapy in a patient with HIV and hepatitis C co-infection.
Croucher AP, Main J.
Int J STD AIDS. 2014 Jan 29.
 Abstract

Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort.
 Roux P, Lions C, Cohen J, Winnock M,  et al
Antivir Ther. 2013 Oct 28. .
 Abstract

Hepatitis C Direct-acting Antiviral Agents: Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients.
 Martel-Laferrière V, Bichoupan K, Dieterich DT
 J Clin Gastroenterol. 2013 Oct 28.
Abstract

Antiretroviral and Anti-Hepatitis C Virus Direct-Acting Antiviral-Related Hepatotoxicity.
Han H, Agarwal R, Martel-Laferriere V, Dieterich DT.
Clin Liver Dis. 2013 Nov;17(4):657-670.
 Abstract

Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.
Hua L, Andersen JW, Daar ES,, et al
AIDS. 2013 Aug 6.
 Abstract

Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Vispo E, Fernández-Montero JV,  et al 
AIDS. 2013 Apr 24;27(7):1187-8
 Abstract

FULL-TEXT PDF ARTICLE
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors
Cassol  E , Misra V, Holman  A, et al
BMC Infectious Diseases 2013, 13:203
 Paper

Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.
Grint D, Peters L, Reekie J,et al
HIV Med. 2013 Mar 27.
 Abstract

Long-term safety and tolerability of nevirapine and efavirenz-containing regimens in HIV/HCV-coinfected patients.
 Mauelshagen A, Horst H, Stellbrink H, Hoffmann C.
J Int AIDS Soc. 2012 Nov 11;15(6):18416.
Abstract

Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria.
Agbaji O, Thio CL, Meloni S,  et al
J Acquir Immune Defic Syndr. 2012 Nov 28.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians.
Ingiliz P, Rockstroh JK
 Liver Int. 2012 Apr 17
 Abstract

Liver Toxicity of Initial Antiretroviral Drug Regimens Including Two Nucleoside Analogs Plus One Non-Nucleoside Analog
or One Ritonavir-Boosted Protease Inhibitor in HIV/HCV-Coinfected Patients.
Macías J, Neukam K, Mallolas J,  et al
HIV Clin Trials. 2012 Mar-Apr;13(2):61-9.
Abstract

Risk of elevated TC/HDL-C ratio after antiretroviral therapy in HIV/HCV patients.
Kakinami L, Block RC, Adams MJ,  et al
AIDS Res Hum Retroviruses. 2012 Mar.
 Abstract

HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
 Jones M, Núñez M.
Curr Opin HIV AIDS. 2011 Nov;6(6):546-52.
 Abstract

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV
co-infected patients.
Plaza Z, Soriano V, Del Mar Gonzalez M, et al
J Antimicrob Chemother. 2011 Sep 27
 Abstract

Natural polymorphisms associated with resistance to new antivirals against HCV in newly
diagnosed HIV-HCV-coinfected patients.
Treviño A, de Mendoza C, Parra P, et al
Antivir Ther. 2011;16(3):413-6..
Abstract

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in
HIV/HCV-coinfected patients.
Trimoulet P, Belzunce C, Faure M,  et al
HIV Med. 2011 Mar 16.
Abstract

Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic
hepatitis C.
Macías J, Neukam K, Portilla J, Iribarren JA,  et al 
J Antimicrob Chemother. 2011 Mar 10
 Abstract

Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression
in HIV-HCV coinfection before and after antiretroviral therapy. 
Potter M, Odueyungbo A, Yang H, et al 
AIDS. 2010 May
 Abstract

Impact of Hepatitis C Virus Coinfection on HAART in HIV-Infected Individuals:
Multicentric Observation Cohort.
 Fuping G, Wei L, Yang H,  et al
J Acquir Immune Defic Syndr. 2010 Apr 26.
 Abstract

Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
 Winters MA, Chary A, Eison R, et al
J Med Virol. 2010 Mar 24;82(5):791-798.
Abstract

Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.
 Iorio A, Marchesini E, Awad T, Gluud LL.
 Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004888.
 Abstract

Sustained Virological Response after Early Antiviral Treatment of Acute Hepatitis C Virus and HIV Coinfection.
 Schulze Zur Wiesch J, Pieper D, et al
Clin Infect Dis. 2009 Jul 6.
 Abstract

Case report: clearance of hepatitis C virus after changing the HAART regimen in a patient infected with hepatitis C virus and the human immunodeficiency virus.
Endo T, Fujimoto K, Nishio M, et al  
J Med Virol. 2009 Jun;81(6):979-82.
 Abstract

HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy.
 Pascual-Pareja JF, Caminoa A, Larrauri C, et al
AIDS. 2009 May 15;23(8):971-5.
 Abstract

Highly active antiretroviral therapy improves ESLD-free survival in HIV-HCV co-infection.
 Ragni MV, Nalesnik MA, Schillo R, Dang Q.
Haemophilia. 2009 Mar;15(2):552-8
 Abstract
 
FULL-TEXT ARTICLE
 Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of HIV-Mono-Infected and HIV/Hepatitis C Co-Infected Cohorts.
 Moodie EE, Pant Pai N, Klein MB.
PLoS ONE. 2009;4(2):e4517.
Paper
 
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection.
 Hofmann WP, Soriano V, Zeuzem S. 
Handb Exp Pharmacol. 2009;189:321-346.
 Abstract
 
The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients.
Carmo RA, Guimarães MD, Moura AS, et al
Braz J Infect Dis. 2008 Jun;12(3):173-9
 Abstract
 
Effect of Antiretroviral Therapy and Hepatitis C Co-infection on Changes in Lipid Levels in HIV-Infected Patients 48 Weeks After Initiation of Therapy.
 Stapleton JT, Bennett K, Bosch RJ, et al 
HIV Clin Trials. 2007 Nov-Dec;8(6):429-36.
 Abstract
 
Case Report: Hepatitis C Virus Activation in HIV-Infected Patients Initiating Highly Active Antiretroviral Therapy.
 Kim HN, Harrington RD, Shuhart MC, et al 
AIDS Patient Care STDS. 2007 Oct;21(10):718-23.
 Abstract
 
Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
 Cooper CL, Mills E.
Int J STD AIDS. 2007 Aug;18(8):546-50.
 Abstract
 
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
 Pineda JA, García-García JA, Aguilar-Guisado M, et al
Hepatology. 2007 Jul 20;
Abstract
 
Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy.
Zeitoun JD, Mallet V, Chaix ML, et al
J Clin Virol. 2007 Jul 18;
 Abstract
 
Early Initiation of Antiretroviral Therapy: The Current Best Way to Reduce Liver-Related Deaths in HIV/Hepatitis C Virus-Coinfected Patients.
Shafran SD
 J Acquir Immune Defic Syndr. 2007 Jan 11;
 Abstract
 
Evaluating Liver Fibrosis Progression and the Impact of Antiretroviral Therapy in HIV and Hepatitis C Coinfection Using a Noninvasive Marker.
 Al-Mohri H, Murphy T, Lu Y,
J Acquir Immune Defic Syndr. 2007 Jan 4;
Abstract
 
Antiretroviral Medication Considerations for Individuals Coinfected with HIV and Hepatitis C Virus.
 Lai AR, Tashima KT, Taylor LE.
AIDS Patient Care STDS. 2006 Oct;20(10):678-92.
 Abstract
 
Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection.
 Parsons TD, Tucker KA, Hall CD, et al 
AIDS. 2006 Aug 1;20(12):1591-5.
 Abstract
 
HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?
 Verma S.
J Antimicrob Chemother. 2006 Jul 19;
Abstract
 
Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
 Sullivan PS, Hanson DL, Teshale EH, et al
AIDS. 2006 May 12;20(8):1171-1179.
 Abstract
 
Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
Sauleda S, Martorell M, Esteban JI,
 Haemophilia. 2006 May;12(3):228-36
 Abstract
 
Impact of Hepatitis C Virus Coinfection on Response to Highly Active Antiretroviral Therapy and Outcome in HIV-Infected Individuals: A Nationwide Cohort Study.
 Weis N, Lindhardt BO, Kronborg G, et al 
Clin Infect Dis. 2006 May 15;42(10):1481-7.
 Abstract
 
Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients.
Guitton E, Montastruc JL, Lapeyre-Mestre M;
Eur J Clin Pharmacol. 2006 Jan 17;
 Abstract
 
Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C
irus-coinfected patients?
 Verma S, Wang CH, Govindarajan S, et al 
Clin Infect Dis. 2006 Jan 15;42(2):262-70.
 Abstract
 
Immunologic Response to Antiretroviral Therapy in Hepatitis C Virus-Coinfected Adults in a Population-Based HIV/AIDS Treatment Program.
Braitstein P, Zala C, Yip B, et al
 J Infect Dis. 2006 Jan 15;193(2):259-68.
 Abstract
 
Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.
 Cooper C, Breau C, Laroche A, et al
HIV Med. 2006 Jan;7(1):32-7.
 Abstract
 
Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.
 Brau N.
J Antimicrob Chemother. 2005 Nov 24;
Abstract
 
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression
using antiretroviral therapy.
 Brau N, Salvatore M, Rios-Bedoya CF, et al 
J Hepatol. 2005 Sep 20;
Abstract

Impact of Hepatitis C Virus on Immune Restoration in HIV-Infected Patients Who Start Highly Active Antiretroviral Therapy: A Meta-analysis.
 Miller MF, Haley C, Koziel MJ, Rowley CF
Clin Infect Dis. 2005 Sep 1;41(5):713-20.
 Abstract
 
Effects of Hepatitis C Virus Coinfection on Survival in Veterans With HIV Treated With Highly Active Antiretroviral Therapy.
 Backus LI, Phillips BR, Boothroyd DB
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):613-619.
Abstract
 
FULL-TEXT ARTICLE
 Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C, Lapadula G, Casari S, et al  
BMC Infect Dis. 2005 Jul 14;5(1):58
 Paper
 
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with
hepatitis C coinfection.
Mocroft A, Phillips AN, Soriano V, et al
AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36.
 Abstract
 
Liver enzymes elevation after HAART in HIV-HCV co-infection.
 Servin-Abad L, Molina E, Baracco G, et al  
J Viral Hepat. 2005 Jul;12(4):429-34.
 Abstract
 
Influence of Liver Fibrosis on Highly Active Antiretroviral Therapy-Associated Hepatotoxicity in Patient swith HIV and Hepatitis C Virus Coinfection.
 Aranzabal L, Casado JL, Moya J, et al
 Clin Infect Dis. 2005 Feb 15;40(4):588-93.
 Abstract
 
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
 Mehta SH, Thomas DL, Torbenson M, et al 
Hepatology. 2004 Dec 23;41(1):123-131
 Abstract
 
Hepatitis C Virus Coinfection Increases Mortality in HIV-Infected Patients in the Highly Active Antiretroviral Therapy Era: Data from the HIV Atlanta VA Cohort Study.
 Anderson KB, Guest JL, Rimland D, et al  
Clin Infect Dis. 2004 Nov 15;39(10):1507-13.
 Abstract
 
Hepatitis C Virus Coinfection Increases Mortality in HIV-Infected Patients in the HighlyActive Antiretroviral Therapy Era: Data from the HIV Atlanta VA Cohort Study.
 Anderson KB, Guest JL, Rimland D, et al  
Clin Infect Dis. 2004 Nov 15;39(10):1507-13.
 Abstract
 
The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy.
 Dorrucci M, Valdarchi C, Suligoi B, et al 
AIDS. 2004 Nov 19;18(17):2313-2318.
 Abstract
 
HIV Infection, hepatitis C infection, and HAART: hard clinical choices.
 Kottilil S, Polis MA, Kovacs JA. et al 
JAMA. 2004 Jul 14;292(2):243-50.
 Abstract
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease
progression in the HIV-NAT cohort.
 Law WP, Duncombe CJ, Mahanontharit A,et al 
AIDS. 2004 May 21;18(8):1169-1177.
 Abstract
 
Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
 Bonacini M.
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S104-8.
 Abstract
 
Impact of highly active antiretroviral therapy on the spectrum of liver disease in hcv-hiv coinfection.
 Sterling RK, Wilson MS, Sanyal AJ, et al 
Clin Gastroenterol Hepatol. 2004 May;2(5):432-9
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C:
harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
 AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
 
Antiretroviral Therapy in Patients with Hepatitis and HIV: Weighing Risks and Benefits.
 Powderly WG.  
Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S109-13.
 Abstract
 
The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune
response.
 Herrero-Martinez E, Sabin CA, et al
J Med Virol. 2004 Feb;72(2):187-93
 Abstract

Impaired Recovery of CD4+ Cell Counts Following Highly Active Antiretroviral Therapy in Drug-Naive Patients Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
 Macias J, Pineda JA, Lozano F, et al
Eur J Clin Microbiol Infect Dis. 2003 Oct 23
Abstract
 
Effect of HAART on HCV viral load in the first three years of follow-up
 Tornero C, Gimeno C, Igual R, et al 
Drug Alcohol Depend. 2003 Oct 24;72(1):13-21
 Abstract
 
The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral Therapy.
Klein MB, Lalonde RG, Suissa S.
Acquir Immune Defic Syndr. 2003 Jul 1;33(3):365-372.
Abstract

Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus
quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.
 Babik JM, Holodniy M.
J Virol 2003 Feb;77(3):1940-50
 Abstract

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA
levels in human immunodeficiency virus and HCV coinfection.
Cooper CL, Cameron DW.
Clin Infect Dis 2002 Oct 1;35(7):873-9
 Abstract

  

     Conference Reports, Abstracts, and Posters

 

Impact of different ART regimens on efficacy and safety of standard HCV treatment in HIV/HCV co-infected patients
 Khaykin P, Vogel M, Voigt E, Rockstroh J, et al
 (4th IAS Conference)
 Abstract
 
The Influence of Genotype 3 Hepatitis C Co-Infection on Liver Enzyme Elevations in HIV-
Infected Patients after Commencement of a New HAART: Results from the MASTER-
EPOKA Cohort   
 C. TORTI, M. PUOTI , G. LAPADULA , et al
(45 ICAAC)
Abstract
 
Risk of Haart-Associated Hepatotoxicity in HIV/HCV Co-Infected Patients with Cirrhosis
 L. ARANZABAL, J.L. CASADO, J. MOYA, et al
(45 ICAAC)
Abstract
 
Hepatotoxicity in HIV-Infected Patients Starting HAART
L. ARANZABAL, J L. CASADO, P. DOMINGO, et al 
(45 ICAAC)
Abstract
 
POSTER
Virologic and immunologic response to antiretroviral therapy among HIV patients
co-infected with hepatitis C virus (HCV) – analysis of a 6,401 HIV patient cohort.
BJ Cowling, CA Donnelly, AC Ghani et al  
(XV International AIDS Conference)
 PDF Poster    Abstract
Abacavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin.
 Laufer N, Laguno M, Perez I, et al  
Antivir Ther. 2008;13(7):953-7
 Abstract
Atazanavir
     
     Journal Papers, Abstracts, and Commentaries
 
 
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
Rivero-Juarez A, Lopez-Cortes LF, Girón-Gonzalez JA, et al
 Lancet Infect Dis. 2014 Jan;14(1):13-4.
 Abstract

The use of atazanavir in hiv infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or meld score.
Rodriguez JM, Hermida JM, Casado JL, et al
AIDS. 2011 Mar 17.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Short-Term Effect of Ritonavir-Boosted Atazanavir in Hepatitis B and/or C Co-infected, Treatment-Experienced HIV Patients.
 Pérez-Elías MJ, Gatell JM, Flores J, et al
HIV Clin Trials. 2009 Jul-Aug;10(4):269-75|
 Abstract

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
 Rodríguez-Nóvoa S, Morello   
 AIDS. 2008 Nov 30;22(18):2535-7
 Abstract

Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
 Pineda JA, Santos J, Rivero A, et al
J Antimicrob Chemother. 2008 Feb 14
Abstract
 
    Conference Reports, Abstracts, and Posters
 
 
Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
 Absalon J, Thal G, Thiry A, Yang R, et al 
(Ninth International Congress on Drug Therapy in HIV Infection)
 Abstract

Pharmacokinetics of atazanavir in HIV-1-HCV co-infected patients
 Gatti F, Nasta P, Matti A, et al
(4th IAS Conference)
 Abstract
Darunavir
     
     Journal Papers, Abstracts, and Commentaries
 
  Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.
 Morsica G, Bianchi G, Bagaglio S,  et al
New Microbiol. 2011 Jul;34(3):317-21
 Abstract

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3.
Rachlis A, Clotet B, Baxter J, et al
HIV Clin Trials. 2007 Jul-Aug;8(4):213-20.
 Abstract
 
    Conference Reports, Abstracts, and Posters
 
  HCV co-infection does not compromised darunavir monotherapy efficacy in HIV-infected patients, though induce higher immune activation profiles
O.-J. Ben-Marzouk Hidalgo, A. Torres-Cornejo, et al
 (XIX International AIDS Conference)
 Abstract

Comparison of liver toxicity in HIV/HCV coinfected and HIV monoinfected patients during 72 weeks ART including darunavir/ritonavir
G. Morsica, G. Bianchi, S. Bagaglio, et al
(XVIII IAC)
 Abstract
   
  Hepatic safety of darunavir 600/100 in HCV coinfected patients with HAART experience
M.A. von Wichmann, M. Saenz-Cuesta, K. Aguirrebengoa, et al
(XVIII IAC)
 Abstract
Didanosine
 

     Journal Papers, Abstracts, and Commentaries

 
Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients.
Vispo E, Maida I, Barreiro P, et al 
HIV Clin Trials. 2008 Jan 1;9(6):440-444
 Abstract
 
Nucleoside analogues and mitochondrial toxicity.
 Fleischer R, Boxwell D, Sherman KE. 
Clin Infect Dis. 2004 Apr 15;38(8):e79-80
 Abstract

Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activityagainst HIV-1 and hepatitis C virus.
 Klein MB, Campeol N, Lalonde RG, et al.  
 AIDS 2003 May 2;17(7):1001-1008
 Abstract

  
Efavirenz
     
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
 Pineda JA, Neukam K, Mallolas J,  et al
J Infect. 2011 Nov 25.
Abstract

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
 Neukam K, Mira JA, Ruiz-Morales J, et al
J Antimicrob Chemother. 2011 Sep 7.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.
 Meynard JL, Lacombe K, Poirier JM,  et al
J Antimicrob Chemother. 2009 Jan 23.
 Abstract

Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
 J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract

Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM of EFV.
 Katsounas A, Frank A, Klinker H, Langmann P. 
Eur J Med Res. 2007 Aug 16;12(8):331-6
 Abstract
Fosamprenavir
     
     Journal Papers, Abstracts, and Commentaries
 
 
Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1-Infected Patients With or Without Hepatitis B or C Coinfection.
 Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M.
HIV Clin Trials. 2012 May-Jun;13(3):171-
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients.
Perrella A, Sbreglia C, D’Antonio A, et al 
Clin Microbiol Infect. 2009 Jul 20.
 Abstract

Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
 Gatti F, Nasta P, Loregian A, Puoti M, et al 
J Antimicrob Chemother. 2009 Jan 16.
 Abstract

Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir
and correlation with plasma levels.
Spagnuolo V, Gentilini G, De Bona A, et al
New Microbiol. 2007 Jul;30(3):279-82.
 Abstract
Lopinavir
 

     Journal Papers, Abstracts, and Commentaries

 
Lopinavir/Ritonavir Pharmacokinetics, Efficacy, and Safety in HIV and Hepatitis B or C Coinfected Adults Without Symptoms of Hepatic Impairment.
Khaykin P, Kotzerke P, Stephan C, et al
Ther Drug Monit. 2014 Apr;36(2):192-20
 Abstract
A WEEK-IN-REVIEW FEATURED REPORT 
FULL-TEXT PDF ARTICLE
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study).
Hasson H, Galli L, Gallotta G, Neri V,  et al 
New Microbiol. 2012 Oct;35(4):469-74
Paper

A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.
 Cooper C, la Porte C, Tossonian H,  et al
HIV Clin Trials. 2012 Jul-Aug;13(4):179-88.
 Abstract

Safety and Pharmacokinetics of Lopinavir in HIV/HCV Coinfected Patients with Advanced Liver Disease.
Casado JL, Del Palacio M, Moya J, et al
HIV Clin Trials. 2011 Sep-Oct;12(5):235-43.
 Abstract

Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Calza L, Mosca L, Pocaterra D, et al
Eur J Clin Pharmacol. 2010 Sep 28
 Abstract

Evolution of HIV and HCV coinfected children receiving long-term lopinavir/ritonavir-based antiretroviral therapy.
 Larrú B, Resino S, Bellón JM, et al
Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):426-9.
 Abstract
 
Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients With or Without Cirrhosis.
 Micheli V, Regazzi M, Dickinson L,
Ther Drug Monit. 2008 Jun;30(3):306-313
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Lopinavir/Ritonavir Pharmacokinetics in HIV and Hepatitis C Virus Co-Infected Patients without Liver Function Impairment : Influence of Liver Fibrosis.
 Molto J, Valle M, Blanco A, Negredo E, et al
Clin Pharmacokinet. 2007;46(1):85-92.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Pharmacokinetics of Lopinavir/Ritonavir in HIV/Hepatitis C Virus-Coinfected Subjects With Hepatic Impairment.
Peng JZ, Pulido F, Causemaker SJ, et al
J Clin Pharmacol. 2006 Mar;46(3):265-74.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract

    Conference Reports, Abstracts, and Posters

  POSTER
No effect of HCV infection on virological response 96 weeks after simplification to lopinavir/ritonavir (LPV/r) monotherapy (MT) in the OK04 trial
 F. Pulido, J. Arribas, OK04 Study Group
(6th IAS Conference)
 Poster      Abstract

POSTER
HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment: final results of a
randomised, proof-of- principle clinical trial (KAMON 2 Study)
H. Hasson, L. Galli, G. Gallotta
 (6th IAS Conference)
 Poster      Abstract
Maraviroc
 
     Journal Papers, Abstracts, and Commentaries
 
  Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
Gagliardini R, Rossetti B, Bianco C,  et al
 J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19818.
 Abstract

Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program.
 Lazzarin A, Than S, Valluri SR, et al
HIV Clin Trials. 2012 Mar-Apr;13(2):83-9
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy.
 Macías J, Viloria MM, Rivero A, et al 
Eur J Clin Microbiol Infect Dis. 2012 Jan 19.
 Abstract

     Conference Reports, Abstracts, and Posters

Maraviroc (MVC) reduces liver stiffness (LS) in HIV-hepatitis C (HCV) co-infected patients
 P. Nasta, F. Gatti, F. Borghi,  et al
(6th IAS Conference)
Abstract
Nelfinavir
 

     Journal Papers, Abstracts, and Commentaries

  Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected
patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE, Shire NJ, Cernohous P, et al
Clin Infect Dis. 2005 Oct 15;41(8):1186-95.
 Abstract
Nevirapine
 

   Journal Papers, Abstracts, and Commentaries

Long-term safety and tolerability of nevirapine and efavirenz-containing regimens in HIV/HCV-coinfected patients.
 Mauelshagen A, Horst H, Stellbrink H, Hoffmann C.
J Int AIDS Soc. 2012 Nov 11;15(6):18416.
Abstract

Association between Exposure to Nevirapine and Reduced Liver Fibrosis Progression in Patients with HIV and Hepatitis C Virus Coinfection.
 Berenguer J, Bellón JM, Miralles P, et al  
Clin Infect Dis. 2008 Jan 1;46(1):137-43.
 Abstract
 
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E, Gutiérrez S, Jahnke N, et al
 AIDS. 2007 Jul 31;21(12):1561-156
 Abstract
 
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
 Macias J, Castellano V, Merchante N, et al.   
AIDS. 2004 Apr 12;18(5):767-774.
 Abstract
Raltegravir
 
   Journal Papers, Abstracts, and Commentaries
 
 

Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals.
Taramasso L, Madeddu G, Ricci E,  et al. 
Biomed Pharmacother. 2015 Feb;69:233-6.
 Abstract

A Switch to Raltegravir Improves Antiretroviral Associated Hepatotoxicity in Individuals Coinfected with HIV and Hepatitis C.
Cevik M, Katsarolis I, J Singh G, Nelson M
J Infect. 2014 May 1.
Abstract

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
 Hernández-Novoa B, Moreno A, Pérez-Elías MJ,  et al 
J Antimicrob Chemother. 2013 Oct 4
 Abstract

Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.
 Cevik M, Jagjit Singh G, Dickinson L, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):18419
 Abstract

Safety and efficacy of raltegravir in patients co-infected with HIV and hepatitis B and/or C virus: complete data from Phase III double-blind studies.
 Rockstroh J, Sklar P, Wan H,  
J Int AIDS Soc. 2012 Nov 11;15(6):18415.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals.
Cevik M, Jagjit Singh G, Dickinson L, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):1841
 Abstract

Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir.
Moreno A, Quereda C, Montes M,  et al
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e47-9
 Abstract

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M,  et al
J Antimicrob Chemother. 2012 Sep 14.
Abstract

    Conference Reports, Abstracts, and Posters

POSTER
Multiple-dose Pharmacokinetics of Raltegravir in Patients Co-infected with HIV/HCV with and without Advanced (Child-Pugh grade C) Hepatic Cirrhosis
B Hernandez-Novoa, A Moreno, M Perez-Elias, et al
 (19 CROI)
PDF Poster     Abstract

POSTER
 Hepatic Safety and Efficacy of Raltegravir in Patients Co-infected with HIV and HBV or HCV
 J Rockstroh, H Teppler, J Zhao, et al
 (17 CROI)
PDF Poster     Abstract
Raltegravir
 
   Journal Papers, Abstracts, and Commentaries
 
  Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C).
Hernández-Novoa B, Moreno A, Pérez-Elías MJ, et al
J Antimicrob Chemother. 2014 Feb;69(2):471-5.
 Abstract
Ritonavir
 
   Journal Papers, Abstracts, and Commentaries
 
  Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
 Neukam K, Mira JA, Ruiz-Morales J, et al
J Antimicrob Chemother. 2011 Sep 7.
Abstract
Stavudine
 

     Conference Reports, Abstracts, and Posters

Population Prevalence of Hepatic Steatosis among Antiretroviral-experienced HCV/HIV Co-infected Adults with and without Stavudine Exposure
 M Sulkowski, S Mehta, R Moore, M Torbenson, et al
 (15th CROI)
Abstract
Tenofovir
 
   Journal Papers, Abstracts, and Commentaries
 
  Role of tenofovir in HIV and hepatitis C virus coinfection.
Tuma P, Vispo E, Barreiro P, Soriano V.
Enferm Infecc Microbiol Clin. 2008 Jun;26(Supl.8):31-37
 Abstract
 

     Conference Reports, Abstracts, and Posters

Renal toxicity in HIV/Hepatitis C co-infected individuals exposed to tenofovir and/or Ribavarin
Jones R., Bower M., Mandalia S., et al
(XVI  International AIDS Conference)
Abstract
Tipranavir
 

     Journal Papers, Abstracts, and Commentaries

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.
Macías J, Orihuela F, Rivero A, et al
 J Antimicrob Chemother. 2008 Oct 24.
Abstract
Zidovudine
 

     Journal Papers, Abstracts, and Commentaries

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
Alvarez D, Dieterich DT, Brau N, et al
 J Viral Hepat. 2006 Oct;13(10):683-9
 Abstract

HIV/HCV Main Page Main New/Newsworthy  Home Page

HIV Antiretroviral Drugs